| Ident. | Authors (with country if any) | Title |
|---|
| 000059 |
JI HYUN KO [Canada] ; Francesca Antonelli [Canada] ; Oury Monchi [Canada] ; Nicola Ray [Canada] ; Pablo Rusjan [Canada] ; Sylvain Houle [Canada] ; Anthony E. Lang [Canada] ; Leigh Christopher [Canada] ; Antonio P. Strafella [Canada] | Prefrontal Dopaminergic Receptor Abnormalities and Executive Functions in Parkinson's Disease |
| 000316 |
Robert A. Hodgson [États-Unis] ; Paul J. Bedard [Canada] ; Geoffrey B. Varty [États-Unis] ; Tatiana M. Kazdoba [États-Unis] ; Therese Di Paolo [Canada] ; Michael E. Grzelak [États-Unis] ; Annamarie J. Pond [États-Unis] ; Abdallah Hadjtahar [Canada] ; Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; Aurelie Dare [Canada] ; Bernard R. Neustadt [États-Unis] ; Andrew W. Stamford [États-Unis] ; John C. Hunter [États-Unis] | Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders |
| 000349 |
Renan P. Souza [Canada] ; Vincenzo De Luca [Canada] ; Gary Remington [Canada] ; Jeffrey A. Lieberman [États-Unis] ; Herbert Y. Meltzer [États-Unis] ; James L. Kennedy [Canada] ; Albert H. C. Wong [Canada] | Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia |
| 000383 |
B. Xu [Canada] ; J. S. Goldman [Canada] ; V. V. Rymar [Canada] ; C. Forget [Canada] ; P. S. Lo [Canada] ; S. J. Bull [Canada] ; E. Vereker [Canada] ; P. A. Barker [Canada] ; L. E. Trudeau [Canada] ; A. F. Sadikot [Canada] ; T. E. Kennedy [Canada] | CRITICAL ROLES FOR THE NETRIN RECEPTOR DELETED IN COLORECTAL CANCER IN DOPAMINERGIC NEURONAL PRECURSOR MIGRATION, AXON GUIDANCE, AND AXON ARBORIZATION |
| 000404 |
Desirae M. Haluk [Canada] ; Stan B. Floresco [Canada] | Ventral Striatal Dopamine Modulation of Different Forms of Behavioral Flexibility |
| 000451 |
Sadayuki Hashioka [Canada] ; Andis Klegeris [Canada] ; Claudia Schwab [Canada] ; Patrick L. Mcgeer [Canada] | Interferon-γ-dependent cytotoxic activation of human astrocytes and astrocytoma cells |
| 000621 |
Daniel Levesque [Canada] ; Claude Rouillard [Canada] | Nur77 and retinoid X receptors : crucial factors in dopamine-related neuroadaptation |
| 000627 |
Catherine R. Mcmillan [Canada] ; Rohita Sharma [Canada] ; Tom Ottenhof [Canada] ; Lennard P. Niles [Canada] | Modulation of tyrosine hydroxylase expression by melatonin in human SH-SY5Y neuroblastoma cells |
| 000681 |
Yuri Ishida [Japon] ; Atsushi Nagai [Japon] ; Shotai Kobayashi [Japon] ; Seung U. Kim [Corée du Sud, Canada] | Upregulation of protease-activated receptor-1 in astrocytes in parkinson disease : Astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase |
| 000697 |
J. Miklossy [Canada] ; D. D. Doudet [Canada] ; C. Schwab [Canada] ; S. Yu [Canada] ; E. G. Mcgeer [Canada] ; P. L. Mcgeer [Canada] | Role of ICAM-1 in persisting inflammation in parkinson disease and MPTP monkeys |
| 000701 |
Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in Parkinsonian monkeys : Implication of preproenkephalin |
| 000757 |
Naomi P. Visanji [Canada] ; Mark J. Millan [France] ; Jonathan M. Brotchie [Canada] | Actions at sites other than D3 receptors mediate the effects of BP897 on L-DOPA-induced hyperactivity in monoamine-depleted rats |
| 000835 |
Sandrine Thuret [Allemagne] ; Kambiz N. Alavian [Allemagne] ; Martin Gassmann [Suisse] ; C. Kent Lloyd [États-Unis] ; Simone M. Smits [Pays-Bas] ; Marten P. Smidt [Pays-Bas] ; Rüdiger Klein [Allemagne] ; Richard H. Dyck [Canada] ; Horst H. Simon [Allemagne] | The neuregulin receptor, ErbB4, is not required for normal development and adult maintenance of the substantia nigra pars compacta |
| 000838 |
J. E. Nash [Canada] ; P. Ravenscroft [Royaume-Uni] ; S. Mcguire [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; F. S. Menniti [États-Unis] ; J. M. Brotchie [Canada] | The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease |
| 000989 |
H. Uri Saragovi [Canada] ; Maria Clara Zaccaro [Canada] | Small molecule peptidomimetic ligands of neurotrophin receptors, identifying binding sites, activation sites and regulatory sites |
| 000D16 |
D. G. Walker [Canada] ; T. G. Beach [Canada] ; REN XU [États-Unis] ; J. Lile [États-Unis] ; K. D. Beck [États-Unis] ; E. G. Mcgeer [Canada] ; P. L. Mcgeer [Canada] | Expression of the proto-oncogene Ret, a component of the GDNF receptor complex, persists in human substantia nigra neurons in Parkinson's disease |
| 000F54 |
K. Mizukawa [Canada] ; E. G. Mcgeer ; P. L. Mcgeer | Autoradiographic study on dopamine uptake sites and their correlation with dopamine levels and their striata from patients with Parkinson disease, alzheimer disease, and neurologically normal controls |
